Johnson & Johnson Innovation-JJDC takes equity stake in Triastek
JNJ•Johnson & Johnson Innovation-JJDC will invest in Triastek under a strategic collaboration on oral medicines, combining Johnson & Johnson’s drug development capabilities with Triastek’s 3D printing technology for oral peptide delivery. The companies entered a Collaboration and License Agreement through Janssen Pharmaceutica NV on Oct. 9, 2026.
1. Equity investment and collaboration
Johnson & Johnson Innovation-JJDC will make an equity investment in Triastek under a strategic oral medicines collaboration. The companies entered a Collaboration and License Agreement through Janssen Pharmaceutica NV on Oct. 9, 2026, pairing Johnson & Johnson’s drug development capabilities with Triastek’s 3D printing technology for oral delivery of peptides.
